BR112021001135A2 - compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico - Google Patents
compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico Download PDFInfo
- Publication number
- BR112021001135A2 BR112021001135A2 BR112021001135-8A BR112021001135A BR112021001135A2 BR 112021001135 A2 BR112021001135 A2 BR 112021001135A2 BR 112021001135 A BR112021001135 A BR 112021001135A BR 112021001135 A2 BR112021001135 A2 BR 112021001135A2
- Authority
- BR
- Brazil
- Prior art keywords
- fenfluramine
- epilepsy
- norfenfluramine
- pharmaceutically acceptable
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| US62/711,051 | 2018-07-27 | ||
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021001135A2 true BR112021001135A2 (pt) | 2021-04-20 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021001135-8A BR112021001135A2 (pt) | 2018-07-27 | 2019-07-26 | compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12558326B2 (https=) |
| EP (1) | EP3829558B1 (https=) |
| JP (1) | JP2021530541A (https=) |
| KR (1) | KR20210061332A (https=) |
| CN (1) | CN112930175A (https=) |
| AU (1) | AU2019310600A1 (https=) |
| BR (1) | BR112021001135A2 (https=) |
| CA (1) | CA3106031A1 (https=) |
| CL (1) | CL2021000196A1 (https=) |
| CO (1) | CO2021002087A2 (https=) |
| CR (1) | CR20210095A (https=) |
| EA (1) | EA202190369A1 (https=) |
| ES (1) | ES2988130T3 (https=) |
| IL (1) | IL280128A (https=) |
| MA (1) | MA53329A (https=) |
| MX (1) | MX2021000987A (https=) |
| PE (1) | PE20211065A1 (https=) |
| PH (1) | PH12021550176A1 (https=) |
| SG (1) | SG11202100682YA (https=) |
| WO (1) | WO2020023923A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| ES3024232T3 (en) | 2015-12-22 | 2025-06-04 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| SG11201900975XA (en) | 2016-08-24 | 2019-03-28 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| MA53488A (fr) * | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
| CN114127150A (zh) * | 2019-07-18 | 2022-03-01 | 巴斯夫欧洲公司 | 脲基甲酸酯基分散剂 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR104F (https=) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| EP0762877B1 (en) * | 1994-06-03 | 2001-03-21 | THEJMDE Trust | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof |
| US6416780B1 (en) | 1997-05-07 | 2002-07-09 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| DK3035926T3 (da) * | 2013-08-19 | 2020-08-31 | Univ California | Forbindelser og fremgangsmåder til behandling af en epilepsilidelse |
| HUE059559T2 (hu) * | 2015-02-25 | 2022-12-28 | Univ California | 5HT agonisták az epilepsziás rendellenességek kezelésére |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| JP2017051788A (ja) | 2016-12-21 | 2017-03-16 | 株式会社三洋物産 | 遊技機 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 US US16/523,568 patent/US12558326B2/en active Active
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202100682YA (en) | 2021-02-25 |
| US20200030260A1 (en) | 2020-01-30 |
| CR20210095A (es) | 2021-06-01 |
| CL2021000196A1 (es) | 2021-12-31 |
| ES2988130T3 (es) | 2024-11-19 |
| WO2020023923A1 (en) | 2020-01-30 |
| CO2021002087A2 (es) | 2021-04-30 |
| EA202190369A1 (ru) | 2021-06-10 |
| CN112930175A (zh) | 2021-06-08 |
| AU2019310600A1 (en) | 2021-02-11 |
| PH12021550176A1 (en) | 2021-10-11 |
| MX2021000987A (es) | 2021-06-15 |
| US12558326B2 (en) | 2026-02-24 |
| IL280128A (en) | 2021-03-01 |
| KR20210061332A (ko) | 2021-05-27 |
| PE20211065A1 (es) | 2021-06-09 |
| EP3829558C0 (en) | 2024-07-03 |
| CA3106031A1 (en) | 2020-01-30 |
| EP3829558A1 (en) | 2021-06-09 |
| MA53329A (fr) | 2022-03-02 |
| EP3829558B1 (en) | 2024-07-03 |
| JP2021530541A (ja) | 2021-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12558326B2 (en) | Method for treating epilepsy | |
| EP3458449B1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| EP3551626B1 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| TWI465452B (zh) | 螺－吲哚酮化合物之鏡像異構物及其作為治療劑之用途 | |
| ES2488618T3 (es) | Compuestos de espiro-oxindol y sus usos como agentes terapéuticos | |
| US20190083420A1 (en) | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders | |
| JP2009524676A (ja) | 精神分裂病を治療するための方法および組成物 | |
| US11325902B2 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| BR112021000209A2 (pt) | Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos | |
| JP2009539780A (ja) | ２０（ｓ）−プロトパナキサジオールの抗うつ薬製造への使用 | |
| US12365650B2 (en) | Deuterated organic compounds and uses thereof | |
| JP6808154B2 (ja) | アダマンタン誘導体およびその使用 | |
| JP7228897B2 (ja) | アダマンチルメチルアミン誘導体およびその医薬としての使用 | |
| HK40045266A (en) | Method for treating epilepsy | |
| HK40016430B (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| HK40016430A (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| JP2023505054A (ja) | 処置方法 | |
| EP4673127A1 (en) | Deuterated and fluorinated empathogens | |
| CA3132179A1 (en) | Method of inhibiting trem-1 | |
| Posner | Novel melatonin MT1 receptor agonists as antidepressants: In vivo electrophysiological and behavioural characterization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2841 DE 17-06-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |